Tulobuterol base is a high-grade bronchodilator, primarily used for managing respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). This potent pharmaceutical ingredient is engineered to target and activate beta-2 adrenoreceptors in the airways, resulting in the relaxation of bronchial smooth muscles and effective bronchodilation. Refarmed Chemicals, a key player in the pharmaceutical industry and now part of the DKSH Group, manufactures Tulobuterol base with a commitment to excellence, as evidenced by compliance with EU GMP certifications and stringent quality controls. The product is presented as a white crystalline powder, with its consistency and purity validated by a comprehensive series of tests including IR, HPLC, and TLC tests. At the onset of use, Tulobuterol base exhibits rapid action within 5-15 minutes and sustains its therapeutic effect for up to 6 hours. Its main application is for the relief and prevention of bronchospasm in patients, thereby improving airway obstruction and lung function. Administered via an aerosol inhaler or nebulizer, dosage and frequency are tailored to individual patient needs and disease severity. The product's reliability is reinforced by its exhaustive assay, showing a 98.5% - 102% active ingredient range, with controlled levels of impurities and residual solvents. Safety is a core aspect of Tulobuterol base's design, having been tested for adverse components. Common side effects may include tachycardia and nervousness, among others. Caution is advised for patients with cardiovascular disease, hypertension, and diabetes. Tulobuterol base is contraindicated for individuals with hypersensitivity to beta-adrenergic agonists, those with thyrotoxicosis or tachyarrhythmias, and it is not recommended for use in children under 12 years of age. As with all medications, potential drug interactions need to be considered, notably with beta-blockers and other beta-adrenergic agonists. This product serves as a testament to Refarmed Chemicals' dedication to providing superior pharmaceutical materials. Through their integration with DKSH, they strive to deliver growth in Asia and beyond, ensuring the availability of quality medical compounds to healthcare providers and patients worldwide.

Products still subject to third-party patent protection might be available solely for R&D purposes.